Table 1 MDS patient characteristics and... | American Society of Hematology

Table 1

MDS patient characteristics and response to miR-21 inhibition

N	Age/Sex	WBC (10³/mL)	Hgb (g/dL)	Plt (10³/mL)	Subtype	Cytogenetics	Colonies post treatment with mismatched control		Colonies post treatment with miR-21 inhibitor
N	Age/Sex	WBC (10³/mL)	Hgb (g/dL)	Plt (10³/mL)	Subtype	Cytogenetics	BFU-E	CFU-GM	BFU-E	CFU-GM
1	63/M	1.2	9	14	RCMD	+11	204	12	259	24
2	79/f	2.9	9.6	29	RAEB	−7q	22	4	26	5
3	68/F	3.5	9.3	35	RAEB	−5q, −18	20	37	49	46
4	70/M	18.2	8.5	84	RAEB	Nml	91	93	121	86
5	69/F	5.2	8.8	75	RCMD	Nml	62	26	98	25

N	Age/Sex	WBC (10³/mL)	Hgb (g/dL)	Plt (10³/mL)	Subtype	Cytogenetics	Colonies post treatment with mismatched control		Colonies post treatment with miR-21 inhibitor
N	Age/Sex	WBC (10³/mL)	Hgb (g/dL)	Plt (10³/mL)	Subtype	Cytogenetics	BFU-E	CFU-GM	BFU-E	CFU-GM
1	63/M	1.2	9	14	RCMD	+11	204	12	259	24
2	79/f	2.9	9.6	29	RAEB	−7q	22	4	26	5
3	68/F	3.5	9.3	35	RAEB	−5q, −18	20	37	49	46
4	70/M	18.2	8.5	84	RAEB	Nml	91	93	121	86
5	69/F	5.2	8.8	75	RCMD	Nml	62	26	98	25

WBC, white blood cells; plt, platelets; Hgb, hemoglobin.